TY - JOUR
T1 - A Randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans
AU - Hennekens, Charles H.
AU - Schneider, Wendy R.
AU - Pokov, Alex
AU - Hetzel, Scott
AU - Demets, David
AU - Serebruany, Victor
AU - Schröder, Henning
PY - 2010/12
Y1 - 2010/12
N2 - Background: We performed the first test in humans of whether aspirin at clinically relevant doses increases nitric oxide (NO) formation. Methods: Seventy primary prevention patients with metabolic syndrome were randomly assigned to 81 mg, 162.5 mg, 325 mg, 650 mg, or 1300 mg aspirin daily for 12 weeks to test changes in heme oxygenase (HO-1), a downstream target of NO formation and asymmetrical dimethylarginine (ADMA), a competitive inhibitor of NO synthase. Findings: For HO-1, the mean was 29.37 nanograms per milliliter at baseline and 57.45 at 12 weeks giving a mean ratio (MR) of 1.96 (P
AB - Background: We performed the first test in humans of whether aspirin at clinically relevant doses increases nitric oxide (NO) formation. Methods: Seventy primary prevention patients with metabolic syndrome were randomly assigned to 81 mg, 162.5 mg, 325 mg, 650 mg, or 1300 mg aspirin daily for 12 weeks to test changes in heme oxygenase (HO-1), a downstream target of NO formation and asymmetrical dimethylarginine (ADMA), a competitive inhibitor of NO synthase. Findings: For HO-1, the mean was 29.37 nanograms per milliliter at baseline and 57.45 at 12 weeks giving a mean ratio (MR) of 1.96 (P
KW - atherosclerosis
KW - cardiovascular disease
KW - endothelium
KW - thrombosis
UR - http://www.scopus.com/inward/record.url?scp=78651331360&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78651331360&partnerID=8YFLogxK
U2 - 10.1177/1074248410375091
DO - 10.1177/1074248410375091
M3 - Article
C2 - 20938039
AN - SCOPUS:78651331360
SN - 1074-2484
VL - 15
SP - 344
EP - 348
JO - Journal of Cardiovascular Pharmacology and Therapeutics
JF - Journal of Cardiovascular Pharmacology and Therapeutics
IS - 4
ER -